PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:
NANOBIOTIX (Euronext:NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenue for the third quarter of 2016.
Income Statement for the third quarter of 2016
| In € | Q3 2016 | Q2 2016 | Q1 2016 | Q3 2015 | |||||||||||||
| Revenues | 58,556 | 936,319 | 45,847 | 47,636 | |||||||||||||
| Of which : | |||||||||||||||||
| License | 46,351 | 936,319 | 45,847 | 46,351 | |||||||||||||
| Services | 12,205 | - | - | 1,285 | |||||||||||||
Year-to-date income statement as of September 30th, 2016
| In € | 09/30/2016 (9 months) | 09/30/2015 (9 months) | ||||||
| Revenues | 1,040,723 | 140,816 | ||||||
| Of which : | ||||||||
| License | 1,028,518 | 137,542 | ||||||
| Services | 12,205 | 3,274 | ||||||
Activity
Nanobiotix’s revenue during the third quarter of 2016 corresponds to the upfront payment (pro-rata share) from its Taiwan-based partner, PharmaEngine. This is within the framework of the licensing contract signed in August 2012 for the development and commercialization of the lead NanoXray product, NBTXR3 in the Asia-Pacific region. The upfront payment amounted €810,640 and is distributed using the straight-line method of apportioning the revenue across the period between the date the contract was signed and the scheduled marketing launch in the region. This upfront payment generated revenue of €46,351 for the third quarter. The invoicing of services totaled €12,205 for Q3 2016.
In total, revenue for the third quarter amounted to €58,556. This brings the revenue for the first nine months of 2016 to €1,040,723, which is fully in line with the Company’s expectations.
During the third quarter of 2016, Nanobiotix reported successful results from European Phase I/II Trial of NBTXR3 in Head & Neck Cancer. A Data Safety Monitoring Board (DSMB) composed by external experts has confirmed (i) the excellent safety profile, with no related serious adverse events, (ii) the feasibility of the injection and (iii) appropriate distribution. The study showed promising signs of tumor volume response in a cancer patient population with a high unmet medical need – patients that cannot receive the standard of care (radiotherapy plus chemotherapy). Based on these promising results, Nanobiotix is currently establishing a clinical development plan, potentially in Europe and USA, which could lead to the registration of NBTXR3 for use in this indication. Click on the following link to download the press release: Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer
On 13 September 2016, Nanobiotix filed for European market approval (CE Mark) for its lead product NBTXR3. The CE Marking submission is based on the current level of evidence generated in the Act.In.Sarc registration trial for treatment of locally-advanced soft tissue sarcoma (STS) and other NBTXR3 clinical trials. The phase II/III clinical trial in Soft Tissue Sarcoma is progressing well towards interim data readout with almost two thirds of the patients randomized. Click on the following link to download the press release: Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe
Finally, on 19 September 2016, Nanobiotix announced that Bpifrance has awarded the Company an interest-free loan of €2M for Innovation (prêt à taux zéro pour l’Innovation – PTZI) to support final development stage of NBTXR3. Click on the following link to download the press release: Bpifrance grants Nanobiotix a 2M€ interest-free loan to support final development stage of lead product, NBTXR3
???
Next financial press release: revenue for Q4 2016 by February 28, 2017
???
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck cancer, prostate cancer, and liver cancers (HCC and liver metastases) as well as head and neck and rectal cancers under trial by PharmaEngine. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.16-0732 on July 22, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
Nanobiotix
Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com
or
Media relations
France - Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
marina@springbok.fr
or
EU Outside France - Instinctif Partners
Melanie Toyne Sewell
+44 (0) 207 457 2020
nanobiotix@instinctif.com
or
United States – The Ruth Group
Kirsten Thomas / Chris Hippolyte
+1 508-280-6592 / +1 646-536-7023
Nanobiotix@theruthgroup.com
